The US FDA has given Zelnorm (tegaserod maleate) the green light to return to the US market with a broad indication for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C) who are at low cardiovascular (CV) risk.
The new label for Zelnorm, a serotonin-4 (5-HT4) receptor agonist now owned by US WorldMeds LLC, contains a...






